Re-challenge of Platinum-based Chemotherapy for Platinum-refractory Patients with Recurrent or Metastatic Head and Neck Cancer: Claims Data Analysis in Japan | Published in Journal of Health Economics and Outcomes Research
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2) | Nature Communications
Searching for a Biomarker for Platinum-Refractory Advanced Epithelial Ovarian Cancer
Anlotinib combined with TQB2450 in patients with platinum-resistant or - refractory ovarian cancer: A multi-center, single-arm, phase 1b trial - ScienceDirect
Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment in: Endocrine-Related Cancer Volume 25 Issue 5 (2018)
A source of hope for platinum-resistant ovarian cancer? - The Lancet
Re-challenge of Platinum-based Chemotherapy for Platinum-refractory Patients with Recurrent or Metastatic Head and Neck Cancer: Claims Data Analysis in Japan | Published in Journal of Health Economics and Outcomes Research
Platinum-free interval affects efficacy of following treatment for platinum- refractory or -resistant ovarian cancer | SpringerLink
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) | Journal for ImmunoTherapy of Cancer | Full Text
Platinum sensitivity is classified as refractory, resistant, or... | Download Scientific Diagram
Platinum sensitivity is classified as refractory, resistant, or... | Download Scientific Diagram
Cancers | Free Full-Text | Platinum Resistance in Ovarian Cancer: Role of DNA Repair
Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study - The Lancet Oncology
Re-challenge of Platinum-based Chemotherapy for Platinum-refractory Patients with Recurrent or Metastatic Head and Neck Cancer: Claims Data Analysis in Japan | Published in Journal of Health Economics and Outcomes Research
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial - The Lancet
VisualAbstract: Adavosertib plus gemcitabine improves survival in platinum-resistant recurrent ovarian cancer | 2 Minute Medicine
Relacorilant Plus Nab-Paclitaxel Extends Survival in Women with Recurrent, Platinum-resistant Ovarian Cancer | BioSpace
Long term outcomes of phase I/II study of palliative triple metronomic chemotherapy in platinum-refractory/early failure oral cancer - The Lancet Regional Health - Southeast Asia
Re-challenge of Platinum-based Chemotherapy for Platinum-refractory Patients with Recurrent or Metastatic Head and Neck Cancer: Claims Data Analysis in Japan | Published in Journal of Health Economics and Outcomes Research
Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need? | Gynecologic Oncology Research and Practice | Full Text
Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives | Journal of Clinical Oncology
Platinum resistance definition by Gynecologic Oncology Group (GOG).... | Download Scientific Diagram
A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer | SpringerLink
